Assenagon Asset Management S.A. Has $5.48 Million Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Assenagon Asset Management S.A. cut its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 51.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,915,729 shares of the company's stock after selling 2,061,395 shares during the period. Assenagon Asset Management S.A. owned approximately 1.45% of Organogenesis worth $5,479,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in shares of Organogenesis by 76.9% in the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company's stock valued at $6,353,000 after buying an additional 986,132 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Organogenesis during the first quarter worth $1,846,000. Acadian Asset Management LLC boosted its position in shares of Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company's stock valued at $8,521,000 after purchasing an additional 471,741 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company's stock valued at $5,702,000 after purchasing an additional 333,123 shares during the period. Finally, Wealth Dimensions Group Ltd. increased its stake in Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company's stock worth $1,142,000 after purchasing an additional 331,840 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Trading Down 3.0 %

ORGO stock traded down $0.09 during mid-day trading on Wednesday, reaching $2.89. 118,014 shares of the stock traded hands, compared to its average volume of 832,309. Organogenesis Holdings Inc. has a 52-week low of $1.96 and a 52-week high of $4.70. The stock's fifty day moving average is $2.88 and its 200-day moving average is $2.77. The company has a market cap of $383.13 million, a P/E ratio of 74.50 and a beta of 1.60. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.11). Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. The firm had revenue of $130.23 million during the quarter, compared to analyst estimates of $122.48 million. As a group, sell-side analysts expect that Organogenesis Holdings Inc. will post -0.17 earnings per share for the current year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.